BIRC2 and prostate cancer: We designed antisense oligonucleotides (ASOs) that simultaneously target BIRC6 and an additional IAP to achieve maximal anti-tumor activity, as elevated expression in prostate cancer has also been reported for other IAPs such as survivin and cIAP1.